Webb5 sep. 2024 · Therachon Holding AG has developed products for the treatment of achondroplasia and short bowel syndrome.These include product candidate TA-46 for the treatment of achondroplasia, “a genetic condition and the most common form of short-limbed dwarfism”, as was reported in a press release from Pfizer.The U.S. … Webb2 juli 2024 · Pfizer has announced it has completed its acquisition of US-based Therachon, a clinical stage biotechnology company focusing on rare diseases; the acquisition was first initiated in early May 2024.. According to the terms of the transaction, the Swiss pharma giant has bought Therachon for $340m with a potential $470m additional payments …
VectivBio Transforming Lives
Webb29 nov. 2024 · Apraglutide, with once-weekly administration, is a potential best-in-class therapeutic for the treatment of short bowel syndrome. BASEL, Switzerland, Nov. 29, 2024 /PRNewswire/ -- Therachon AG ... Webb8 maj 2024 · Therachon is a clinical-stage global biotechnology company focused on the discovery and development of innovative treatment for severe, rare conditions with … earlyne chaney wikipedia
Pfizer cuts eight programs, including dwarfism drug at center of ...
WebbTherAchon is a biotech company specializing in research and development. It is engaged in the development of a recombinant protein therapy for achondroplasia, the most … WebbECHOPULSE. FOR FIBROADENOMA AND THYROID NODULES. ECHOPULSE® is a completely non-invasive robot for echotherapy treatment of thyroid nodules and breast … WebbDevelopment group, serving as its Global Head for Integration Management and Global Head of Alliance Management. His work included the integration of Wyeth, Hospira, Anacor, Medivation, Therachon, Array and most recently Amplyx. He also directly led the separation of. 09 Apr 2024 21:53:51 earlynes sylacauga al